Ad
related to: response evaluation criteria for cancer research and treatment- Make A Sustained Impact
Donate a small amount every month
to support ongoing cancer research.
- What is Immunotherapy?
Unleash the power of the immune
system to fight cancer.
- Ways to Give Back
Donate, fundraise, shop, or match.
Make a charitable bequest, registry
- Why Donate?
We can change the way cancer is
treated and cured. Make an impact.
- Make A Sustained Impact
Search results
Results from the WOW.Com Content Network
Response evaluation criteria in solid tumors (RECIST) is a set of published rules that define when tumors in cancer patients improve ("respond"), stay the same ("stabilize"), or worsen ("progress") during treatment. The criteria were published in February 2000 by an international collaboration including the European Organisation for Research ...
The immune-related response criteria (irRC) is a set of published rules that define when tumors in cancer patients improve ("respond"), stay the same ("stabilize"), or worsen ("progress") during treatment, where the compound being evaluated is an immuno-oncology drug.
PET response criteria in solid tumors (PERCIST) is a set of rules that define when tumors in cancer patients improve ("respond"), stay the same ("stabilize"), or worsen ("progress") during treatment, using positron emission tomography (PET). The criteria were published in May 2009 in the Journal of Nuclear Medicine (JNM). [1]
The response rate is the percentage of patients on whom a therapy has some defined effect; for example, the cancer shrinks or disappears after treatment. [9] When used as a clinical endpoint for trials of cancer treatments, this is often called the objective response rate (ORR).
The Common Terminology Criteria for Adverse Events (CTCAE), [1] formerly called the Common Toxicity Criteria (CTC or NCI-CTC), are a set of criteria for the standardized classification of adverse events of drugs and treatment used in cancer therapy. The CTCAE system is a product of the US National Cancer Institute (NCI).
All cancer treatment modalities (e.g., chemotherapy, targeted drugs, radiation and surgery) trigger systemic and local effects in the treated subject (i.e., the host). These include a rapid elevation in the levels of circulating cytokines , chemokines , growth factors and enzymes accompanied by acute mobilization and tumor homing of bone-marrow ...
A tumor marker is a biomarker that can be used to indicate the presence of cancer or the behavior of cancers (measure progression or response to therapy). They can be found in bodily fluids or tissue. Markers can help with assessing prognosis, surveilling patients after surgical removal of tumors, and even predicting drug-response and monitor ...
Cancer research is research into cancer to identify causes and develop strategies for prevention, diagnosis, treatment, and cure. Cancer research ranges from epidemiology, molecular bioscience to the performance of clinical trials to evaluate and compare applications of the various cancer treatments.
Ad
related to: response evaluation criteria for cancer research and treatment